BenevolentAl Therapeutics Pipeline and Triage
Non-Alcoholic SteatoHepatitis (NASH)
Affects 11% US population (1), 63 million
patients in 7MM (2), forecast $27.2bn market by
2029(3)
Non-alcoholic fatty liver disease (NAFLD) is a metabolic
disorder characterised by accumulation of fatty deposits in
the liver; non-alcoholic steatohepatitis (NASH) occurs when
NAFLD progresses, and is associated with liver inflammation,
fatty deposits, and fibrosis
High unmet need - NAFLD and NASH pose a high economic
burden, driven by costs to provide chronic care for patients
(including liver transplants) in the absence of any disease
modifying therapy; currently hard to detect meaning NASH is
often diagnosed later in the disease course
30%
27%
Fibrosis
Staging 0-1
Fibrosis
Staging 2
NASH
25%
17%
Fibrosis
Staging 3
USA, Japan, EU5 (4)
Fibrosis
Staging 4
(Cirrhosis)
NASH Fibrosis Staging (0-4), percentage of diagnosed Prevalent Cases of NASH, ≥18 Years,
BAI-5030: (Target A) Best-in-class, potent and
selective drug for the treatment of NASH.
(Target B) First-in-class programme
• Targets A and B were identified by our TargetID platform
as entirely novel targets for the treatment of NASH -
representing mechanistically distinct approaches
• We are currently applying our Hit Identification (Target
B) and Hit expansion (Target A) capabilities to support
the identification of potent and selective inhibitors
• BAI-5030 is expected to provide efficacious,
mechanistically differentiated, disease modifying
.
treatments for NASH, with the potential to reduce fibrosis
in both early and late stages of disease
BAI-5030 will target fibrosis (and potentially steatosis) in
NASH, meeting the unmet need for patients including:
О
Lack of currently approved therapies
High mortality and prevalence of NASH
Severe disease progression in absence of disease
modifying therapy, including development of
cirrhosis and hepatocellular carcinoma
Source (1), (2), (3) and (4):GlobalData, Non-Alcoholic Steatohepatitis (NASH): Opportunity Analysis and
Forecasts to 2029
Benevolent 59
AlView entire presentation